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A competitive solid-phase immunoassay for the determination of testosterone in serum samples using time- 
resolved fluorescence is described. The solid phase is a testosterone-3-(O-carboxymethyl)-oxime-ovalbu- 
min conjugate coated to polystyrene microtiter strips. Europium-labelled polyclonal and monoclonal 
antibodies against testosterone-3-(0-carboxymethyl)-oxime-bovine serum albumin were compared. 
Their behavior was quite similar although the polyclonal antibody was more sensitive, giving a detection 
limit of 15 fmol testosterone per assay. Correlation with RIA was very good (r = 0.982 and y = 
-0.150+0.969x). 
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1. INTRODUCTION 2. EXPERIMENTAL 
In recent years immunoassays based on time- 
resolved fluorimetry [6] have proved to be an alter- 
native method to RIA [3-51. Because of the long 
decay fluorescence of the europium chelate used as 
marker, disturbing fluorescence from other com- 
ponents of the sample is avoided [6]. Other 
features of the method are the short counting time, 
only 1 s per sample, and the stability of the label 
as compared to radioactive isotopes. 
2.1. Purification and labelling of antibodies 
We describe here a simple time-resolved 
fluoroimmunoassay (TR-FIA) for testosterone, in 
which monoclonal or polyclonal antibodies are 
labelled with a europium chelate. The antigen, in 
the form of a testosterone-3-CMO-OVA con- 
jugate, is fixed by adsorption to the surface of 
polystyrene microtiter strips. This is the first assay 
for hapten molecules using the principle of time- 
resolved fluorescence. 
Monoclonal rat antibodies to testosterone-3- 
CMO-BSA (clone Hs) were purified from ascites 
fluid by Na$Od precipitation and dialyzed over- 
night at 4°C against 0.05 M KzHP04. Polyclonal 
rabbit antitestosterone-3-CMO-BSA antibodies 
were purified from serum in the same way. The an- 
tibodies were labelled with an isothiocyanatophen- 
yl-EDTA-Eu chelate as in [l], and purified from 
excess label on a 1.5 x 45 cm Sepharose 6B column 
using 0.05 M Tris-HCl buffer (pH 7.4) containing 
0.9% NaCl and 0.05% NaN3 as eluent. The 
europium-to-protein ratio in the labelled 
monoclonal and polyclonal antibody preparations 
was 7 and 6, respectively. The preparations were 
stored as such at 4°C. 
* To whom correspondence should be addressed 
Abbreviations: CMO, carboxymethyl oxime; BSA, 
bovine serum albumin; OVA, ovalbumin 
2.2. Preparation of testosterone-3-CMO- 
ovalbumin conjugate 
The testosterone-3-CMO-OVA conjugate was 
prepared essentially as in [2]. A cold solution of 
0.5 mg testosterone-3-CMO-Nhydroxysuccini- 
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mide in 0.1 ml dioxane was carefully added to 3.1 
mg ovalbumin in 1.6 ml of 0.05 M phosphate buf- 
fer (pH 7.3) containing 0.1% gelatin, 0.9% NaCl 
and 0.1% NaN3 (molar testosterone-to-ovalbumin 
ratio -15). The reaction mixture was held at 4°C 
for 2 h after which it was centrifuged at 2000 x g 
for 15 min. The conjugate was purified from ex- 
cess testosterone derivative by gel filtration on 
Sephadex G-25 M (column PD 10, Pharmacia, 
Sweden). Elution was performed with 0.05 M 
phosphate buffer containing 0.1% NaN3. The pro- 
tein concentration in the conjugate preparation 
was 470pg/ml, and the total protein yield was 
about 50%. Analysis of the ultraviolet absorption 
spectra of the conjugate indicated a testosterone- 
to-ovalbumin ratio of 0.8. 
2.3. Coating of polystyrene microtiter strips 
The testosterone-3-CMO-OVA conjugate was 
immobilized by adsorption to the well walls of 
polystyrene microtiter strips (Eflab, Helsinki). One 
strip comprises 12 wells and the dimensions of each 
well are 6.5 x 11 mm. The wells were coated over- 
night at room temperature with 0.25 ml of a 
0.05 pg/ml conjugate solution diluted in 0.1 M 
sodium carbonate buffer (pH 9.3). After coating 
the wells were washed with 0.9% saline containing 
0.05% NaN3 using the Nunc Immuno-Wash 
system. Finally, the wells were dried and stored at 
room temperature in plastic bags over silica gel un- 
til use. 
2.4, Extraction of serum samples 
One hundred ~1 of serum-based standards or 
unknown samples were extracted for 15 min in 
1 ml freshly prepared diethyl ether-ethyl acetate 
(9: 1): 400~1 of the ether phase was evaporated 
under a stream of air, 120 ~1 of assay buffer was 
added and the sample was left for at least 30 min 
before 50-~1 samples in duplicate were taken for 
testosterone measurement. The assay buffer con- 
tained 0.9% NaCl, 0.05% NaN3, 0.5% BSA, 
0.05% bovine globulin, 0.01% Tween-40 and 
20 PM diethylenetriaminepentaacetic acid in 
0.05 M Tris-HCl buffer (pH 7.7). 
2.5. Time-resolved jluoroimmunoassay 
Fifty ~1 of standards in assay buffer or 50 ~1 ex- 
tracted serum-based standards or samples were 
added to the coated wells: 200 ,J antibody solution 
214 
(containing 25 ng labelled antibody diluted in 
assay buffer) was then added. The immunoreac- 
tion took place at room temperature for 1.5 h and 
was stopped by washing 3 times with 0.9% NaCl 
containing 0.05% NaN3. 
2.6. Measurement of fluorescence 
The Eu bound to the solid phase was dissociated 
into the solution and measured as a 2-naphthoyltri- 
fluoroacetone chelate [l] using the single photon 
counting time-resolved fluorimeter in [7]. 
3. RESULTS AND DISCUSSION 
The conjugate concentration used for coating of 
the microtiter strip wells was found to give optimal 
replacement for both the polyclonal and 
monoclonal antibodies. In 1.5 h incubation assays 
the obtained fluorescence was directly dependent 
on the concentration of the labelled monoclonal 
antibody up to 25 ng. In a prolonged incubation 
overnight, at which the reaction had reached 
equilibrium, the fluorescence was directly propor- 
tional to the label concentration up to 10 ng/well, 
whereafter the antigenic solid phase was saturated. 
An antibody concentration exceeding 50 ng gave a 
marked reduction on replacement. It was found 
that 25 ng of antibodies per assay gave enough 
high cps values as well as optimal replacement. 
This concentration was optimal for both 
polyclonal and monoclonal antibodies. 
Dose-response curves obtained with the two 
labels at optimal conditions are shown in fig.lA. 
The polyclonal label was more sensitive in the 
assay. Taking a C.V. value of 13% as the highest 
acceptable limit, the lower detectable concentra- 
tion is 0.3 nmol/l or 15 fmol/assay, which is com- 
parable to most commercial RIA kits usually hav- 
ing a detection limit of 5-30 fmol. For the 
monoclonal antibody this concentration was 
lo-times higher. The measuring range with the 
polyclonal label was 0.3-10 nmol/l and for the 
monoclonal label 3.0-100 nmol/l. The precision 
profile of the assays is shown in fig.lB. 
Cross-reactions in the competitive solid-phase 
immunoassay were compared to the data obtained 
with conventional RIA measurements reported by 
the manufacturers of the antibodies (table 1). The 
results obtained were essentially the same as in 
RIA. Thus, labelling of the antibodies with the 
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Fig.1. (A) Dose-response curves for TR-FIA of 
testosterone. Monoclonal antibody (0; B, = 
226855 cps), polyclonal antibody (0; & = 219709 cps). 
(B) Precision profile of the immunoassay. Nine 
duplicates were run for each concentration. 
europium chelate does not affect their apparent 
properties. 
Because of the cross-reaction properties and the 
higher sensitivity obtained, the polyclonal an- 
tibody was chosen for testosterone determination 
y = -0,150+0,961r 
I = 0,982 
n= 11 
kb~ter~ne,nmd/~ (TR-FIA) 
Fig.2. Correlation between the TR-FIA of testosterone 
and a commercial RIA. Male samples (o), female 
samples ( n ). 
in extracted serum samples. Fig.2 illustrates the 
correlation between the TR-FIA and a commercial 
RIA on 5 female and 6 male samples. The correla- 
tion was found to be very good (r = 0.982). 
In conclusion, the TR-FIA of testosterone was 
proved to be a very sensitive and reproducible test. 
The main features of the assay are its simplicity 
(only two pipettings and no centrifugation step), 
short fluorescence counting time (1 s), stability of 
the fluorescent probe and the avoidance of hazard- 
ous radioactivity. 
Table 1 
Cross-reactions expressed as percentages at a level of 5Ot70 replacement 
for testosterone using polyclonal and monoclonal antibodies in TR-FIA 
and RIA measurements 
Compound Monoclonal label Polyclonal label 
Testosterone 
Sm-Dihydrotestosterone 
S,&Dihydrotestosterone 
17~Epitestosterone 
Androstenedione 
Estradiol 
Progesterone 
Cortisol 
FIA RIA 
100 100 
100 100 
1.0 0.5 
0.1 0.2 
0.4 <O.l 
co.1 _ 
1.9 <O.l 
co.1 <O.l 
FIA RIA 
100 100 
28 30 
31 25 
0.1 0.8 
2.5 0.2 
<O.l < 0.05 
<O.l - 
<O.l &0.0005 
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